Search clinical trials for: Interferon injections and ribavirin

Total 8937 results

Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Hoffmann-La Roche

Completed

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Hepatitis C, Chronic

Canada
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Melanoma
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Fremantle Hospital and Health Service

Completed

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

Hepatitis C

Australia
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Bristol-Myers Squibb

Completed

Ph IIA Study (SOC +/- NS5B) (HEPCAT)

Hepatitis C Virus

United States
Merck Sharp & Dohme LLC

Completed

Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)

Hepatitis C, Chronic | Hepatitis C Virus
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
Bristol-Myers Squibb

Completed

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Hepatitis C

United States, Puerto Rico
Brooke Army Medical Center
InterMune

Completed

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Hepatitis C
Tehran University of Medical Sciences

Completed

The Effect of Adding Metformin to the Treatment of Hepatitis C

Hepatitis C

Iran, Islamic Republic of
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

United States
University of Southern California

Terminated

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Thrombocytopenia | Hepatitis C Infection

United States
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
Bristol-Myers Squibb

Completed

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

Hepatitis C Virus

Australia, France, United States, Spain, Italy, Netherlands, Romania, Russian Federation
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Hepatitis C

United States, Belgium
Cairo University
Egyptian Railway Hospital

Completed

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Chronic Hepatitis c

Egypt
Gilead Sciences

Approved for marketing

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Post-transplant Hepatitis C
Medtronic Corporate Technologies and New Ventures

Completed

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C (COPE-HCV)

Hepatitis C

United States
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
Hoffmann-La Roche

Completed

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

Hepatitis C, Chronic

Brazil
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico
National Liver Institute, Egypt
Cairo University; Ain Shams University; Yassin Abdelghaffar Charity Center for... and other collaborators

Completed

Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV

Hepatitis C, Chronic

Egypt
French National Agency for Research on AIDS and...

Unknown

Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Fibrosis | Hepatitis C, Chronic

France
French National Agency for Research on AIDS and...
Schering-Plough

Terminated

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Hepatitis C, Chronic

France
Ain Shams University
Schering-Plough; Tempus Labs; Fulbright; International Society for Infectious Diseases

Completed

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Hepatitis C

Egypt
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
National Institute of Allergy and Infectious Diseases...

Completed

A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood

Chronic Granulomatous Disease

United States
Merck Sharp & Dohme LLC

Completed

Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (Pegade)

Hepatitis C, Chronic
Hoffmann-La Roche
Roche Pharma AG

Completed

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

Hepatitis C, Chronic

Germany
Louis Stokes VA Medical Center

Completed

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Hepatitis C, Chronic | Cirrhosis

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
National Institute of Allergy and Infectious Diseases...

Completed

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients (HEPCPR)

HIV Infections | Hepatitis C

United States
Changhai Hospital

Completed

Optimization of Antiviral Therapy of Chronic HBV Infection

Hepatitis B | Adverse Effects | Australia Antigen Positive

China
TaiGen Biotechnology Co., Ltd.

Completed

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

Hepatitis C, Chronic

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

Leukocyte Adhesion Deficiency Syndrome

United States
SPP Pharmaclon Ltd.

Recruiting

Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis

Pulmonary Tuberculosis

Russian Federation
SPP Pharmaclon Ltd.

Completed

Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia

Community-acquired Pneumonia

Russian Federation
Bristol-Myers Squibb

Terminated

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
National Institute of Allergy and Infectious Diseases...

Completed

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Healthy | Mycobacterium Infections, Atypical

United States

3

Subscribe